Detalhe da pesquisa
1.
Integration of genomic data enables selective discovery of breast cancer drivers.
Cell
; 159(6): 1461-75, 2014 Dec 04.
Artigo
Inglês
| MEDLINE | ID: mdl-25433701
2.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Lancet Oncol
; 24(3): 273-285, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36858723
3.
The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland.
Genes Dev
; 28(7): 765-82, 2014 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-24636986
4.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33152285
5.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 33-43, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31838010
6.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 22(1): 120, 2020 11 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33138866
7.
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.
Future Oncol
; 16(24): 1801-1813, 2020 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-32633563
8.
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
Breast Cancer Res
; 21(1): 108, 2019 09 18.
Artigo
Inglês
| MEDLINE | ID: mdl-31533777
9.
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
Breast Cancer Res
; 17(1): 149, 2015 Dec 08.
Artigo
Inglês
| MEDLINE | ID: mdl-26643555
10.
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
NPJ Breast Cancer
; 10(1): 20, 2024 Mar 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38448600
11.
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.
EBioMedicine
; 102: 105043, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38447275
12.
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
J Natl Cancer Inst
; 115(3): 332-336, 2023 03 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36576009
13.
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
JAMA Oncol
; 9(6): 835-840, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37103927
14.
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.
Nat Commun
; 14(1): 1157, 2023 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36859416
15.
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
JAMA Oncol
; 9(6): 841-846, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37103916
16.
Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
Breast Cancer Res
; 19(1): 49, 2017 04 19.
Artigo
Inglês
| MEDLINE | ID: mdl-28424080
17.
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
Eur J Cancer
; 174: 232-242, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36067616
18.
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
EBioMedicine
; 85: 104320, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-36374768
19.
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.
Clin Cancer Res
; 28(5): 993-1003, 2022 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34907082
20.
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
EBioMedicine
; 75: 103801, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34990895